/
We are a San Diego-based commercial-stage biopharmaceutical company committed to commercializing innovative products to address unmet needs in women s sexual and reproductive health. Our first commercial product, PHEXX , was approved by the FDA on May 22, 2020, for the prevention of pregnancy and launched in the U.S. in September 2020.
16.71% operating margin is respectable but not wide. ROIC at 1218.81%. Suggests the business covers its cost of capital, but doesn't point to a wide moat.
Revenue grew 4.2%, steady but not accelerating.
Negative free cash flow of -$2M. The business is consuming cash, not generating it.
Profitability & Returns
Revenue (TTM)
$20M
▲ +4.2% YoY
Net Income (TTM)
-$6M
▲ +104.4% YoY
Op. Margin
-7.53%
▲ +56.3pp YoY
ROIC
-308.31%
▲ +4905.2pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$251K
▲ +48.8% YoY
Op. Cash Flow (TTM)
-$251K
▲ +48.7% YoY
Net Debt
-$1M
Net Cash Position
Cash & Equiv.
$1M
5Y CAGR: +114.4%
Continue Research